DK2251344T3 - Formulering af boronsyreforbindelser - Google Patents
Formulering af boronsyreforbindelser Download PDFInfo
- Publication number
- DK2251344T3 DK2251344T3 DK10006835.2T DK10006835T DK2251344T3 DK 2251344 T3 DK2251344 T3 DK 2251344T3 DK 10006835 T DK10006835 T DK 10006835T DK 2251344 T3 DK2251344 T3 DK 2251344T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- boronic acid
- alkyl
- aryl
- mannitol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract description 66
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 title abstract description 43
- 238000009472 formulation Methods 0.000 title description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 104
- -1 boronic acid compound Chemical class 0.000 claims abstract description 63
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 105
- 235000010355 mannitol Nutrition 0.000 claims description 67
- 125000003118 aryl group Chemical group 0.000 claims description 63
- 239000002253 acid Substances 0.000 claims description 45
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 31
- 229930195725 Mannitol Natural products 0.000 claims description 29
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 29
- 239000000594 mannitol Substances 0.000 claims description 29
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 26
- 125000004429 atom Chemical group 0.000 claims description 25
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 125000003277 amino group Chemical group 0.000 claims description 12
- 229910052798 chalcogen Inorganic materials 0.000 claims description 12
- 150000001787 chalcogens Chemical class 0.000 claims description 12
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 11
- 229910052796 boron Inorganic materials 0.000 claims description 11
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 5
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 3
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 abstract description 36
- 238000000034 method Methods 0.000 abstract description 35
- 239000012736 aqueous medium Substances 0.000 abstract description 3
- 125000000217 alkyl group Chemical group 0.000 description 59
- 239000004395 L-leucine Substances 0.000 description 34
- 229960003136 leucine Drugs 0.000 description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000600 sorbitol Substances 0.000 description 10
- 235000010356 sorbitol Nutrition 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 150000001642 boronic acid derivatives Chemical class 0.000 description 9
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000008176 lyophilized powder Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000012931 lyophilized formulation Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 239000003125 aqueous solvent Substances 0.000 description 5
- 125000005620 boronic acid group Chemical class 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 150000002016 disaccharides Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 150000002772 monosaccharides Chemical group 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940079156 Proteasome inhibitor Drugs 0.000 description 3
- 125000004442 acylamino group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000003207 proteasome inhibitor Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- PFURGBBHAOXLIO-UHFFFAOYSA-N cyclohexane-1,2-diol Chemical compound OC1CCCCC1O PFURGBBHAOXLIO-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- MOILFCKRQFQVFS-BDNRQGISSA-N (1r,3s,4r,5r)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol Chemical compound C1[C@@H]2C(C)(C)[C@H]1C[C@H](O)[C@@]2(O)C MOILFCKRQFQVFS-BDNRQGISSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- GKDCWKGUOZVDFX-UHFFFAOYSA-N 1,1,1,4,4,4-hexafluoro-2,3-bis(trifluoromethyl)butane-2,3-diol Chemical compound FC(F)(F)C(C(F)(F)F)(O)C(O)(C(F)(F)F)C(F)(F)F GKDCWKGUOZVDFX-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- QPKFVRWIISEVCW-UHFFFAOYSA-N 1-butane boronic acid Chemical compound CCCCB(O)O QPKFVRWIISEVCW-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 125000006549 C4-C10 aryl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-VRPWFDPXSA-N D-fructopyranose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-VRPWFDPXSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100027612 Kallikrein-11 Human genes 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 101710152431 Trypsin-like protease Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000037012 chymotrypsin-like activity Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000026374 cyclin catabolic process Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Claims (2)
1
i i -(:ι;λλ,λ1 ,iwor —ί"ΗΛ„ΛιΛ mannitol og en forbindelse med formlen (1): (l) hvor P er hydrogen eller en amino-gruppebeskyttende enhed; R er hydrogen eller Ci-12-alkyl; A er 0, 1 eller 2; R1, R2 og R3 hver især uafhængigt er hydrogen, Ci-12-alkyl, C3-i2-cykloalkyl, Ce-14-aryl eller -CH2-R5; R5, i hvert tilfælde, er C6-i4-aryl, (C6-i4)ar(Ci-i2)-alkyl, (Ci-i2)alk(C6-i4)-aryl, C3.
i2-cykloalkyl, heterocyclyl omfattende 3 til 8 atomer, hvor et eller flere atomer er valgt blandt N, O og S, heteroaryl omfattende 5 til 14 atomer, hvor 1-4 atomer er valgt blandt N, O og S eller -W-R6, hvor W er et chalcogen, og R6 er Ci--i2-alkyl; hvor ringdelen af hvert aryl, aralkyl, alkaryl, cykloalkyl, heterocyclyl eller heteroaryl i R1, R2, R3 eller R5 eventuelt kan være substitueret; og Z1 og Z2 sammen danner en enhed, der er afledt af mannitol, hvor atomet, der er vedhæftet til boron i hvert tilfælde er et oxygenatom, og hvor forbindelsen med formlen (1) er lyofiliseret, og hvor forbindelsen er en mannitolester af A/-(2-pyrazin)carbonyl-L-phenylalanin-L-leucinboronsyre.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26416001P | 2001-01-25 | 2001-01-25 | |
| EP02709145A EP1355910B1 (en) | 2001-01-25 | 2002-01-25 | Formulation of boronic acid compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2251344T3 true DK2251344T3 (da) | 2016-05-09 |
| DK2251344T4 DK2251344T4 (da) | 2024-05-13 |
Family
ID=23004871
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02709145.3T DK1355910T3 (da) | 2001-01-25 | 2002-01-25 | Formulering af borsyreforbindelser |
| DK16157001.5T DK3078667T3 (da) | 2001-01-25 | 2002-01-25 | Formulering af borsyreforbindelser |
| DK10006835.2T DK2251344T4 (da) | 2001-01-25 | 2002-01-25 | Formulering af boronsyreforbindelser |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02709145.3T DK1355910T3 (da) | 2001-01-25 | 2002-01-25 | Formulering af borsyreforbindelser |
| DK16157001.5T DK3078667T3 (da) | 2001-01-25 | 2002-01-25 | Formulering af borsyreforbindelser |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US6713446B2 (da) |
| EP (4) | EP2251344B2 (da) |
| JP (2) | JP4162491B2 (da) |
| AT (1) | ATE501157T1 (da) |
| AU (1) | AU2002243646B2 (da) |
| CA (2) | CA2435146C (da) |
| CY (2) | CY1111488T1 (da) |
| DE (1) | DE60239384D1 (da) |
| DK (3) | DK1355910T3 (da) |
| ES (3) | ES2359391T3 (da) |
| FI (1) | FI2251344T4 (da) |
| HK (1) | HK1149936A1 (da) |
| PT (2) | PT1355910E (da) |
| TR (1) | TR201819416T4 (da) |
| WO (2) | WO2002059130A1 (da) |
Families Citing this family (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US6713446B2 (en) * | 2001-01-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Formulation of boronic acid compounds |
| US20050176651A1 (en) * | 2002-09-09 | 2005-08-11 | Trigen Limited | Peptide boronic acids useful in making salts thereof |
| US20060084592A1 (en) * | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
| US7112572B2 (en) * | 2002-09-09 | 2006-09-26 | Trigen Limited | Multivalent metal salts of boronic acids |
| EP1396269A1 (en) * | 2002-09-09 | 2004-03-10 | Trigen Limited | Boronic acid salts of multivalent metals used in the preparation of a medicament for treating thrombosis |
| US20050282757A1 (en) * | 2002-09-09 | 2005-12-22 | Trigen Limited | Peptide boronic acid compounds useful in anticoagulation |
| US20050119226A1 (en) * | 2003-09-09 | 2005-06-02 | Trigen Limited | Methods for synthesizing organoboronic compounds and products thereof |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US20060052390A1 (en) * | 2003-12-24 | 2006-03-09 | Scios, Inc. | Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition |
| GB0405272D0 (en) * | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
| AU2016202747B2 (en) * | 2004-03-30 | 2017-11-23 | Millennium Pharmaceuticals, Inc. | Synthesis of boronic ester and acid compounds |
| DK3385267T3 (da) * | 2004-03-30 | 2021-11-01 | Millennium Pharm Inc | Syntese af boronestere og syreforbindelser |
| AU2011265442B2 (en) * | 2004-03-30 | 2014-12-04 | Millennium Pharmaceuticals, Inc. | Synthesis of boronic ester and acid compounds |
| WO2006012395A2 (en) | 2004-07-23 | 2006-02-02 | Susan Marie Royalty | Peptidase inhibitors |
| TW200618820A (en) * | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
| US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
| US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US20060252740A1 (en) * | 2005-04-29 | 2006-11-09 | Johnson Robert G Jr | Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor |
| AU2006202209B2 (en) * | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
| PL1888123T3 (pl) * | 2005-06-08 | 2013-06-28 | Janssen Biotech Inc | Terapia komórkowa chorób degeneracyjnych oka |
| DK2623113T3 (da) | 2005-11-09 | 2017-07-17 | Onyx Therapeutics Inc | Forbindelse til enzymhæmning |
| US8741643B2 (en) * | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| US7691852B2 (en) | 2006-06-19 | 2010-04-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| CA2606634A1 (en) * | 2006-12-08 | 2008-06-08 | Centenary Institute Of Cancer Medicine And Cell Biology | Assay for response to proteasome inhibitors |
| US9080145B2 (en) * | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| EP2185693B1 (en) | 2007-07-31 | 2019-07-03 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
| SI2178888T1 (sl) * | 2007-08-06 | 2012-11-30 | Millennium Pharm Inc | Proteasomni inhibitorji |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| AU2016253697A1 (en) * | 2007-08-06 | 2016-11-24 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| EA034601B1 (ru) * | 2007-08-06 | 2020-02-25 | Милленниум Фармасьютикалз, Инк. | Способ получения бороновых кислот |
| WO2009036281A2 (en) * | 2007-09-12 | 2009-03-19 | Dr. Reddy's Laboratories Ltd. | Bortezomib and process for producing same |
| DK2207791T4 (da) | 2007-10-04 | 2019-10-07 | Onyx Therapeutics Inc | Krystallinske peptidepoxyketon-proteasehæmmere og syntese af aminosyreketoepoxider |
| WO2009051581A1 (en) | 2007-10-16 | 2009-04-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| US7838673B2 (en) | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| EP2229434B1 (en) * | 2007-11-27 | 2011-09-07 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
| CA2959401C (en) | 2008-02-21 | 2021-12-07 | Centocor Ortho Biotech Inc. | Methods, surface modified plates and compositions for cell attachment, cultivation and detachment |
| AU2013203964B2 (en) * | 2008-06-17 | 2015-04-23 | Takeda Pharmaceutical Company Limited | Boronate ester compounds and pharmaceutical compositions thereof |
| SG194349A1 (en) * | 2008-06-17 | 2013-11-29 | Millennium Pharm Inc | Boronate ester compounds and pharmaceutical compositions thereof |
| EP2310492B1 (en) | 2008-06-30 | 2015-07-22 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
| US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| EP2344165A4 (en) * | 2008-10-01 | 2012-12-05 | Reddys Lab Ltd Dr | PHARMACEUTICAL COMPOSITIONS COMPRISING BORONIC ACID COMPOUNDS |
| ES2617560T3 (es) | 2008-10-21 | 2017-06-19 | Onyx Therapeutics, Inc. | Combinación del inhibidor del proteasoma de epoxicetona peptídica carfilzomib con melfalán para su uso en el tratamiento del mieloma múltiple |
| CA2742268C (en) | 2008-10-31 | 2020-02-18 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
| US9012218B2 (en) * | 2008-10-31 | 2015-04-21 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| AU2009316583B2 (en) * | 2008-11-20 | 2016-04-21 | Janssen Biotech, Inc. | Methods and compositions for cell attachment and cultivation on planar substrates |
| RU2555538C2 (ru) | 2008-11-20 | 2015-07-10 | Сентокор Орто Байотек Инк. | Культура плюрипотентных стволовых клеток на микроносителях |
| EA201170921A1 (ru) * | 2009-01-09 | 2012-01-30 | Сан Фарма Адвансед Ресёрч Компани Лимитед | Фармацевтическая композиция |
| BRPI1006189A2 (pt) | 2009-03-12 | 2020-08-18 | Genentech Inc | uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| AU2010229988B9 (en) | 2009-03-24 | 2015-09-17 | Janssen Pharmaceutica Nv | Biomarkers for assessing peripheral neuropathy response to treatment with a proteasome inhibitor |
| EP2238973A1 (en) * | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
| CN101928329B (zh) * | 2009-06-19 | 2013-07-17 | 北京大学 | 三肽硼酸(酯)类化合物、其制备方法和应用 |
| BR112012001480A2 (pt) | 2009-07-20 | 2015-09-01 | Janssen Biotech Inc | Diferenciação de células-tronco embriônicas humanas |
| GB2485113B (en) | 2009-07-20 | 2016-12-28 | Janssen Biotech Inc | Differentiation of human embryonic stem cells into cells of the pancreatic endoderm lineage |
| CN102482640B (zh) * | 2009-07-20 | 2015-03-11 | 詹森生物科技公司 | 人胚胎干细胞的分化 |
| JP5567136B2 (ja) | 2009-09-08 | 2014-08-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ４−置換ピリジン−３−イル−カルボキサミド化合物及び使用方法 |
| ES2624644T3 (es) | 2009-10-01 | 2017-07-17 | Janssen Pharmaceutica, N.V. | Inhibidores de proteasoma para el tratamiento de cáncer |
| EP2498793B1 (en) | 2009-11-13 | 2019-07-10 | Onyx Therapeutics, Inc. | Oprozomib for use in metastasis suppression |
| CA2785300A1 (en) | 2009-12-22 | 2011-07-21 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
| US9150833B2 (en) | 2009-12-23 | 2015-10-06 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| RU2664864C1 (ru) | 2009-12-23 | 2018-08-23 | Янссен Байотек, Инк. | Способы увеличения экспрессии ngn3 и nkx6.1 в эндокринных клетках поджелудочной железы |
| WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
| WO2011109279A2 (en) * | 2010-03-01 | 2011-09-09 | Centocor Ortho Biotech Inc. | Methods for purifying cells derived from pluripotent stem cells |
| US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
| RU2529800C2 (ru) * | 2010-03-18 | 2014-09-27 | ИННОФАРМА, Инк. | Стабильные составы бортезомиба |
| NZ602622A (en) | 2010-03-31 | 2015-01-30 | Millennium Pharm Inc | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| WO2011136905A2 (en) | 2010-04-07 | 2011-11-03 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
| EP2566571A4 (en) * | 2010-05-05 | 2013-11-20 | Univ Winthrop Hospital | REDUNDANT PACEMAKER SYSTEM WITH GUIDED AND IMMEDIATE STEERING CONTROL |
| CN102884176B (zh) | 2010-05-12 | 2017-09-05 | 詹森生物科技公司 | 人胚胎干细胞的分化 |
| AU2011255647A1 (en) | 2010-05-18 | 2012-11-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| PL2611909T3 (pl) | 2010-08-31 | 2018-05-30 | Janssen Biotech, Inc | Zróżnicowanie ludzkich embrionalnych komórek macierzystych |
| RU2673946C1 (ru) | 2010-08-31 | 2018-12-03 | Янссен Байотек, Инк. | Дифференцирование плюрипотентных стволовых клеток |
| PL2611910T3 (pl) | 2010-08-31 | 2018-06-29 | Janssen Biotech, Inc | Różnicowanie ludzkich embrionalnych komórek macierzystych |
| US9126997B1 (en) | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
| WO2012047845A1 (en) * | 2010-10-05 | 2012-04-12 | App Pharmaceuticals | Bortezomib formulations stabilised with boric |
| WO2012048745A1 (en) | 2010-10-14 | 2012-04-19 | Synthon Bv | Process for making bortezomib and intermediates for the process |
| RS55053B1 (sr) | 2011-08-11 | 2016-12-30 | Janssen Pharmaceutica Nv | Prediktori za lečenje kancera |
| PT2744332T (pt) | 2011-08-19 | 2017-01-24 | Glaxo Group Ltd | Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c |
| EP2776586B1 (en) | 2011-11-11 | 2018-03-07 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| CA2855356A1 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| BR112014015417A8 (pt) | 2011-12-22 | 2017-07-04 | Janssen Biotech Inc | diferenciação de células-tronco embrionárias humanas em células positivas de insulina hormonal únicas |
| WO2013112601A1 (en) | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
| CA2862320A1 (en) | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Method of treatment of nasopharyngeal cancer |
| AU2013227219A1 (en) | 2012-03-02 | 2014-10-23 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions comprising boronic acid compounds |
| AU2013230020B2 (en) | 2012-03-07 | 2018-08-09 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
| CA2784240C (en) | 2012-03-27 | 2014-07-08 | Innopharma, Inc. | Stable bortezomib formulations |
| CN104334719B (zh) | 2012-06-08 | 2018-02-13 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌细胞的分化 |
| EA021179B1 (ru) * | 2012-06-15 | 2015-04-30 | Ощество С Ограниченной Ответственностью "Тева" | Лиофилизат соединения бороновой кислоты |
| EP2869820A4 (en) | 2012-07-09 | 2016-02-17 | Onyx Therapeutics Inc | PRODRUGS OF PEPTIDEPOXIDE KETONE PROTEASE INHIBITORS |
| BR112015005343A2 (pt) | 2012-09-11 | 2017-07-04 | Cipla Ltd | processo para a preparação de bortezomib, composto, bortezomib ou seu anidrido, e, processo para a preparação de um composto |
| NZ630287A (en) | 2012-11-16 | 2016-07-29 | Shilpa Medicare Ltd | Crystalline bortezomib process |
| MX2015008619A (es) | 2012-12-31 | 2016-01-12 | Janssen Biotech Inc | Suspension y agrupamiento de celulas humanas pluripotentes para la diferenciacion a celulas endocrinas pancreaticas. |
| MX2015008578A (es) | 2012-12-31 | 2015-09-07 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas mediante el uso de relugadores de hb9. |
| RU2018116647A (ru) | 2012-12-31 | 2018-10-24 | Янссен Байотек, Инк. | Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| CN103070835B (zh) * | 2013-01-31 | 2015-01-07 | 江苏奥赛康药业股份有限公司 | 一种含硼替佐米的冻干组合物及其制备方法 |
| US10023611B2 (en) | 2013-04-16 | 2018-07-17 | Cipla Limited | Process for the preparation of bortezomib mannitol ester |
| JP6165986B2 (ja) * | 2013-08-23 | 2017-07-19 | シントン・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂ．Ｖ． | ボルテゾミブを含む医薬組成物 |
| CN105705149A (zh) | 2013-10-03 | 2016-06-22 | 米伦纽姆医药公司 | 用于预防或治疗系统性红斑狼疮和/或狼疮性肾炎的方法 |
| CN104586776B (zh) * | 2013-10-30 | 2017-05-17 | 扬子江药业集团上海海尼药业有限公司 | 以硼替佐米为活性成分的制剂及其制备方法 |
| WO2015076359A1 (ja) * | 2013-11-21 | 2015-05-28 | 国立大学法人北海道大学 | プロテアソーム阻害性化合物 |
| CN106132970B (zh) * | 2014-02-03 | 2020-09-04 | 俄亥俄州创新基金会 | 硼酸酯和其药物制剂 |
| RU2694311C2 (ru) | 2014-05-16 | 2019-07-11 | Янссен Байотек, Инк. | Применение малых молекул для увеличения экспрессии mafa в панкреатических эндокринных клетках |
| JP2017524652A (ja) | 2014-05-20 | 2017-08-31 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 |
| DE102014010218A1 (de) | 2014-07-10 | 2016-01-14 | Immunologik Gmbh | Mittel zur Behandlung retroviraler Infektionen |
| DE102014010220A1 (de) | 2014-07-10 | 2016-01-14 | Immunologik Gmbh | Mittel zur Behandlung retroviraler Infektionen |
| EP4180041A1 (en) | 2014-08-07 | 2023-05-17 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| EP3031811A1 (en) | 2014-12-09 | 2016-06-15 | Teva Pharmaceuticals Ltd. | Malic acid esters of bortezomib |
| WO2016110870A1 (en) | 2015-01-07 | 2016-07-14 | Emcure Pharmaceuticals Limited | Pharmaceutical composition of bortezomid |
| MA41505A (fr) * | 2015-02-11 | 2017-12-19 | Millennium Pharm Inc | Nouvelle forme cristalline d'un inhibiteur de protéasome |
| JP2018510859A (ja) * | 2015-03-17 | 2018-04-19 | レオン−ナノドラッグズ ゲーエムベーハー | 安定化されたボロン酸化合物を含むナノ粒子 |
| KR101891728B1 (ko) * | 2015-04-20 | 2018-08-24 | 동아에스티 주식회사 | 펩타이드 붕소산 화합물을 함유하는 안정화 약학 제제 |
| US9752093B2 (en) * | 2015-06-04 | 2017-09-05 | Chevron Oronite Company Llc | Borated polyol ester of hindered phenol antioxidant/friction modifier with enhanced performance |
| EP3120836A1 (de) | 2015-07-22 | 2017-01-25 | Stada Arzneimittel Ag | Gebrauchsfertige bortezomib-lösung |
| EP3120837A1 (de) | 2015-07-22 | 2017-01-25 | Stada Arzneimittel Ag | Verfahren zur herstellung einer bortezomibester-lösung |
| MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
| JP6223508B2 (ja) * | 2016-06-27 | 2017-11-01 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | プロテアソーム阻害剤 |
| WO2018038687A1 (en) | 2016-08-22 | 2018-03-01 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex |
| EP3565549B1 (en) | 2017-01-09 | 2022-03-09 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| EP3585448A1 (en) | 2017-02-24 | 2020-01-01 | Bayer Aktiengesellschaft | Use of radium ra-223 chloride for the treatment of multiple myeloma |
| EP3589659A4 (en) | 2017-02-28 | 2021-03-24 | Mayo Foundation for Medical Education and Research | CANCER TREATMENT COMPOUNDS AND METHODS |
| CN106916177B (zh) * | 2017-03-23 | 2019-04-23 | 南京陵瑞医药科技有限公司 | 一种氘代的二肽硼酸或其酯类化合物及其合成方法与用途 |
| JP2018177649A (ja) * | 2017-04-04 | 2018-11-15 | 日本化薬株式会社 | ボルテゾミブを含有する医薬組成物 |
| CN108794516A (zh) * | 2017-04-26 | 2018-11-13 | 上海时莱生物技术有限公司 | 硼酸和硼酸酯类化合物及其制备方法和用途 |
| RU2659160C1 (ru) * | 2017-07-10 | 2018-06-28 | Акционерное Общество "Фарм-Синтез" | Способ получения лиофилизата бортезомиба и фармацевтическая композиция, содержащая бортезомиб в форме стабильного лиофилизованного продукта, полученная указанным способом |
| BR112020005079A2 (pt) | 2017-09-14 | 2020-09-15 | Glaxosmithkline Intellectual Property Development Limited | tratamento de combinação para câncer |
| JP2018024694A (ja) * | 2017-10-03 | 2018-02-15 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | プロテアソーム阻害剤 |
| JP7423028B2 (ja) | 2017-11-01 | 2024-01-29 | 日医工岐阜工場株式会社 | ボルテゾミブを含有する凍結乾燥医薬組成物 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| CA3087565A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| EP3746065A4 (en) | 2018-01-29 | 2022-02-16 | Cognos Therapeutics Inc. | INTRATUMORAL ADMINISTRATION OF BORTEZOMIB |
| US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| CN108451911B (zh) * | 2018-04-04 | 2020-05-22 | 重庆惠源医药有限公司 | 一种硼替佐米制剂的制备方法 |
| EP3781139A1 (en) | 2018-04-18 | 2021-02-24 | F. Hoffmann-La Roche AG | Combination therapy with a bet inhibitor and a proteasome inhibitor |
| CN110540547A (zh) | 2018-05-28 | 2019-12-06 | 秦艳茹 | 一种肽硼酸酯类化合物的合成与用途 |
| US20210393656A1 (en) * | 2019-01-11 | 2021-12-23 | Intas Pharmaceuticals Ltd. | A process for preparation of a stable pharmaceutical composition of bortezomib |
| JP7387330B2 (ja) * | 2019-08-09 | 2023-11-28 | 東和薬品株式会社 | ボルテゾミブ保存用容器 |
| US11986486B2 (en) * | 2020-11-02 | 2024-05-21 | Spes Pharmaceuticals Inc. | Aqueous compositions of bortezomib |
| US20230062279A1 (en) | 2021-08-12 | 2023-03-02 | Extrovis Ag | Pharmaceutical compositions of bortezomib |
| US11679119B2 (en) | 2021-09-24 | 2023-06-20 | MAIA Pharmaceuticals, Inc. | Bortezomib compositions |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
| WO2024069240A2 (en) | 2022-09-29 | 2024-04-04 | Takeda Pharmaceutical Company Limited | Cd38-binding fusion protein combination therapy |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5825042B2 (ja) * | 1979-08-10 | 1983-05-25 | 科学技術庁無機材質研究所長 | 衝撃圧縮によるダイヤモンド粉末の合成法 |
| FI60700C (fi) | 1980-04-09 | 1982-03-10 | Ksv Chemicals Oy | Foerfarande foer framstaellning av 1,2-diacyl-sn-glyceroler |
| US4434188A (en) * | 1981-12-17 | 1984-02-28 | National Institute For Researches In Inorganic Materials | Method for synthesizing diamond |
| IT1153974B (it) | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| DE3502902A1 (de) * | 1984-01-31 | 1985-08-08 | Futaba Denshi Kogyo K.K., Mobara, Chiba | Ionenstrahl-aufdampfvorrichtung |
| US4743522A (en) * | 1985-09-13 | 1988-05-10 | Minolta Camera Kabushiki Kaisha | Photosensitive member with hydrogen-containing carbon layer |
| JPS63107898A (ja) * | 1986-10-23 | 1988-05-12 | Natl Inst For Res In Inorg Mater | プラズマを用いるダイヤモンドの合成法 |
| US5250720A (en) | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| US4822466A (en) * | 1987-06-25 | 1989-04-18 | University Of Houston - University Park | Chemically bonded diamond films and method for producing same |
| US4816291A (en) * | 1987-08-19 | 1989-03-28 | The Regents Of The University Of California | Process for making diamond, doped diamond, diamond-cubic boron nitride composite films |
| JPS6461396A (en) * | 1987-09-01 | 1989-03-08 | Idemitsu Petrochemical Co | Synthesis of diamond and installation therefor |
| NZ226170A (en) | 1987-09-18 | 1990-07-26 | Ethicon Inc | Stable freeze-dried pharmaceutical composition containing epidermal growth factor |
| EP0315574A3 (de) * | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
| US4925701A (en) * | 1988-05-27 | 1990-05-15 | Xerox Corporation | Processes for the preparation of polycrystalline diamond films |
| US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| US4928629A (en) * | 1988-06-13 | 1990-05-29 | Iowa State University Research Foundation, Inc. | Egg inoculation method |
| US4862529A (en) * | 1988-07-13 | 1989-09-05 | Hill-Rom Company, Inc. | Hospital bed convertible to chair |
| US4919974A (en) * | 1989-01-12 | 1990-04-24 | Ford Motor Company | Making diamond composite coated cutting tools |
| JP2730145B2 (ja) * | 1989-03-07 | 1998-03-25 | 住友電気工業株式会社 | 単結晶ダイヤモンド層の形成法 |
| US5082359A (en) * | 1989-11-28 | 1992-01-21 | Epion Corporation | Diamond films and method of growing diamond films on nondiamond substrates |
| US4954365A (en) * | 1989-12-18 | 1990-09-04 | The United States Of America As Represented By The Secretary Of The Army | Method of preparing a thin diamond film |
| US5071677A (en) * | 1990-05-24 | 1991-12-10 | Houston Advanced Research Center | Halogen-assisted chemical vapor deposition of diamond |
| CA2049673A1 (en) * | 1990-11-26 | 1992-05-27 | James F. Fleischer | Cvd diamond by alternating chemical reactions |
| US5989511A (en) * | 1991-11-25 | 1999-11-23 | The University Of Chicago | Smooth diamond films as low friction, long wear surfaces |
| US5620512A (en) * | 1993-10-27 | 1997-04-15 | University Of Chicago | Diamond film growth from fullerene precursors |
| US5772760A (en) * | 1991-11-25 | 1998-06-30 | The University Of Chicago | Method for the preparation of nanocrystalline diamond thin films |
| US6592839B2 (en) * | 1991-11-25 | 2003-07-15 | The University Of Chicago | Tailoring nanocrystalline diamond film properties |
| US5849079A (en) * | 1991-11-25 | 1998-12-15 | The University Of Chicago | Diamond film growth argon-carbon plasmas |
| US5209916A (en) * | 1991-11-25 | 1993-05-11 | Gruen Dieter M | Conversion of fullerenes to diamond |
| US5370855A (en) * | 1991-11-25 | 1994-12-06 | Gruen; Dieter M. | Conversion of fullerenes to diamond |
| US5360477A (en) * | 1992-03-04 | 1994-11-01 | Semiconductor Energy Laboratory Co., Ltd. | Method for forming diamond and apparatus for forming the same |
| US5505953A (en) | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
| US5439492A (en) * | 1992-06-11 | 1995-08-08 | General Electric Company | Fine grain diamond workpieces |
| US5273788A (en) * | 1992-07-20 | 1993-12-28 | The University Of Utah | Preparation of diamond and diamond-like thin films |
| US5449531A (en) * | 1992-11-09 | 1995-09-12 | North Carolina State University | Method of fabricating oriented diamond films on nondiamond substrates and related structures |
| US5308661A (en) * | 1993-03-03 | 1994-05-03 | The Regents Of The University Of California | Pretreatment process for forming a smooth surface diamond film on a carbon-coated substrate |
| US5935944A (en) | 1993-09-10 | 1999-08-10 | Neutron Technology Corporation | Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA) |
| US5492900A (en) | 1993-09-10 | 1996-02-20 | Neutron Technology Corporation | Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA) |
| TW280770B (da) | 1993-10-15 | 1996-07-11 | Takeda Pharm Industry Co Ltd | |
| US5574017A (en) | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US5614649A (en) | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
| US5897924A (en) * | 1995-06-26 | 1999-04-27 | Board Of Trustees Operating Michigan State University | Process for depositing adherent diamond thin films |
| CA2281224A1 (en) | 1997-02-15 | 1998-08-20 | Proscript, Inc. | Treatment of infarcts through inhibition of nf-kappab |
| US5962049A (en) | 1997-03-31 | 1999-10-05 | Miljkovic; Dusan | Boron carbohydrate complexes and uses thereof |
| EP1017398A1 (en) | 1997-09-25 | 2000-07-12 | Proscript, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
| US5985842A (en) | 1998-05-14 | 1999-11-16 | Miljkovic; Dusan | Boron compounds/complexes to control hair growth, and methods of use |
| US5935994A (en) | 1998-05-29 | 1999-08-10 | Nimni; Marcel E. | Nutritionally balanced dermal composition and method |
| US6169076B1 (en) | 1999-03-31 | 2001-01-02 | Glcosyn Pharmaceuticals, Inc. | P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols |
| AU5788800A (en) | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| US6422077B1 (en) * | 2000-04-06 | 2002-07-23 | The University Of Chicago | Ultrananocrystalline diamond cantilever wide dynamic range acceleration/vibration/pressure sensor |
| US6783589B2 (en) * | 2001-01-19 | 2004-08-31 | Chevron U.S.A. Inc. | Diamondoid-containing materials in microelectronics |
| US6713446B2 (en) | 2001-01-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Formulation of boronic acid compounds |
| US6619076B2 (en) * | 2001-10-12 | 2003-09-16 | David W. Boling | Method and apparatus for cooking starch |
-
2002
- 2002-01-25 US US10/056,567 patent/US6713446B2/en not_active Expired - Lifetime
- 2002-01-25 FI FIEP10006835.2T patent/FI2251344T4/fi active
- 2002-01-25 DK DK02709145.3T patent/DK1355910T3/da active
- 2002-01-25 ES ES02709145T patent/ES2359391T3/es not_active Expired - Lifetime
- 2002-01-25 DE DE60239384T patent/DE60239384D1/de not_active Expired - Lifetime
- 2002-01-25 CA CA2435146A patent/CA2435146C/en not_active Expired - Lifetime
- 2002-01-25 WO PCT/US2002/001907 patent/WO2002059130A1/en active Application Filing
- 2002-01-25 AT AT02709145T patent/ATE501157T1/de active
- 2002-01-25 PT PT02709145T patent/PT1355910E/pt unknown
- 2002-01-25 DK DK16157001.5T patent/DK3078667T3/da active
- 2002-01-25 AU AU2002243646A patent/AU2002243646B2/en not_active Expired
- 2002-01-25 EP EP10006835.2A patent/EP2251344B2/en not_active Expired - Lifetime
- 2002-01-25 JP JP2002559432A patent/JP4162491B2/ja not_active Expired - Lifetime
- 2002-01-25 DK DK10006835.2T patent/DK2251344T4/da active
- 2002-01-25 EP EP02709145A patent/EP1355910B1/en not_active Revoked
- 2002-01-25 ES ES16157001T patent/ES2702732T3/es not_active Expired - Lifetime
- 2002-01-25 EP EP02718868A patent/EP1360189A1/en active Pending
- 2002-01-25 PT PT16157001T patent/PT3078667T/pt unknown
- 2002-01-25 ES ES10006835T patent/ES2571219T3/es not_active Expired - Lifetime
- 2002-01-25 EP EP16157001.5A patent/EP3078667B1/en not_active Expired - Lifetime
- 2002-01-25 US US10/056,563 patent/US6699835B2/en not_active Expired - Lifetime
- 2002-01-25 JP JP2002559433A patent/JP2004517932A/ja not_active Abandoned
- 2002-01-25 TR TR2018/19416T patent/TR201819416T4/tr unknown
- 2002-01-25 WO PCT/US2002/002086 patent/WO2002059131A1/en active Application Filing
- 2002-01-25 CA CA002435124A patent/CA2435124A1/en not_active Abandoned
-
2003
- 2003-09-18 US US10/664,732 patent/US6958319B2/en not_active Expired - Lifetime
- 2003-12-23 US US10/744,843 patent/US7109323B2/en not_active Expired - Lifetime
-
2005
- 2005-07-19 US US11/184,622 patent/US20050282742A1/en not_active Abandoned
-
2011
- 2011-03-31 HK HK11103293.5A patent/HK1149936A1/zh not_active IP Right Cessation
- 2011-05-23 CY CY20111100504T patent/CY1111488T1/el unknown
-
2018
- 2018-12-11 CY CY20181101322T patent/CY1121142T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2251344T3 (da) | Formulering af boronsyreforbindelser | |
| AU2002243646A1 (en) | Formulation of boronic acid compounds | |
| AU2009260778B2 (en) | Boronate ester compounds and pharmaceutical compositions thereof | |
| ES2899606T3 (es) | Síntesis de compuestos de ésteres y ácidos borónicos | |
| KR102122416B1 (ko) | 세포독성 디펩티드의 동결건조 제제 | |
| CA2376965A1 (en) | Peptide boronic acid inhibitors of hepatitis c virus protease | |
| WO2012131707A2 (en) | Novel crystalline form of bortezomib, process for the preparation and pharmaceutical composition thereof | |
| EP2819673B1 (en) | Pharmaceutical compositions comprising boronic acid compounds | |
| AU2002249979A1 (en) | Formulation of boronic acid compounds | |
| KR102122429B1 (ko) | 세포독성 디펩티드의 동결건조 제제 | |
| Hsiao | Design, synthesis and biological evaluation of boron-containing pentapeptides ascAMP-dependent protein kinase inhibitors | |
| AU2013204497A1 (en) | Boronate ester compounds and pharmaceutical compositions thereof | |
| AU2013202996A1 (en) | Synthesis of boronic ester and acid compounds |